Navigation Links
Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives
Date:12/3/2008

operations through 2010 based on current expense projections.

Preclinical / Research

-- Publication of data supporting Sangamo's first ZFN Therapeutic program for the treatment of HIV/AIDS in high-impact journal Nature Biotechnology demonstrating highly efficient and specific ZFN-modification of CCR5 in human T-cells resulting in an increase in CD4 T-cell counts and a reduction in viral load in an animal model of HIV infection (Perez et al., 2008, Nat Biotechnol.,26: 808).

-- Nature Biotechnology publication establishing the utility of ZFNs in the generation of transgenic animals and the potential broadening of the production of knockout transgenic models beyond mouse models (Doyon et al., 2008, Nat. Biotechnol. 26: 702).

-- Publication of data in the journal Proceedings of the National Academy of Sciences (PNAS) establishing Sangamo's ZFN technology as a new approach for rapid generation of "knock-out" cell lines (Santiago et al., 2008, PNAS 105: 5809).

Select 2009 Objectives

During the briefing Sangamo will also discuss the following objectives for 2009:

-- Sangamo expects to file an IND for SB-313 to evaluate the drug in a Phase 1 trial in subjects with glioblastoma.

-- The company expects to present data from its three ongoing Phase 2 clinical trials of SB-509 in subjects with DN, SB-509-601 in subjects with mild to moderate DN, SB-509-701 subjects with moderate to severe DN with a blocked nerve and SB-509-703 in stem cell mobilization.

-- Establishment of a strategic partnership for SB-509.

-- Sangamo estimates that it expects to end 2009 with approximately $40M in cash and cash equivalents, based on current expense projections and expected progress in existing corporate relationships.

The presentation from today's Investor and Analyst Briefing will be archived on Sangamo's website and is a
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
2. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
3. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
4. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
7. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
8. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
11. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... On Thursday, July 10, 2014, the NASDAQ ... Average finished the day 0.42% lower at 16,915.07, and the ... broad based as eight out of ten sectors ended the ... ended the day at 711.88, down 0.02%, while the index ... initiated coverage on the following equities: Covidien PLC (NYSE: ...
(Date:7/11/2014)... , July 11, 2014 Research ... addition of the "Immunoprotein Diagnostic Testing Market ... the highest CAGR of 6% and is expected ... report to their offering. ... immunoprotein diagnostic testing has been segmented according to ...
(Date:7/11/2014)... LONDON , July 11, 2014 /PRNewswire/ ... of visitors to Safety & Health Expo ... by the move to London ... senior management attending exhibition.     ... (Photo: http://photos.prnewswire.com/prnh/20140711/696892-a ) ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
... NoviPet , a leading global provider of ... supplements for dogs at the Backer,s 24th Annual Pet Industry ... 2012, in Atlantic City, New Jersey. The new dietary ... City Convention Center. NoviPet intends to widen its offerings in the ...
... Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" ... Distribution Specialists, LLC ("HDS") are pleased to announce that ... ("Agreement") with a major pro sports team based in ... of Clotamin.  The Agreement is part of new marketing ...
Cached Medicine Technology:NoviPet to Present New Food Supplements for Dogs at Pet Industry Spring Trade Show 2Sunpeaks Ventures Signs Advertising and Promotion Agreement With Another Major Sports Team - Clotamin To Be Sold at All Walgreens Locations Throughout Arizona 2Sunpeaks Ventures Signs Advertising and Promotion Agreement With Another Major Sports Team - Clotamin To Be Sold at All Walgreens Locations Throughout Arizona 3
(Date:7/14/2014)... Encino, CA (PRWEB) July 14, 2014 ... Dental Group is now offering Lumineers and ... more extensive procedures that require more preparation and greater ... use porcelain tooth-shaped shells to conceal visible flaws on ... Dr. Sabbagh-Fard work closely with patients to ensure they ...
(Date:7/14/2014)... Barbara Bronson Gray ... News) -- New research suggests that a faltering sense ... disease, and that an inexpensive, low-tech smell test could ... In two different studies, the decreased ability to identify ... function and progression to Alzheimer,s disease. "We,re trying ...
(Date:7/14/2014)... Kathleen Doheny HealthDay ... Losing a spouse may be linked to multiple health issues, ... study. For certain seniors, widowhood may even delay dementia, ... memory problem, losing the spouse was associated with a later ... married," said study researcher Dr. Bryan Woodruff. Woodruff, ...
(Date:7/14/2014)... Connecticut (PRWEB) July 14, 2014 ... is celebrating its Grand Opening on Monday, July ... Connecticut 06830. The celebration will last all week ... all new patients. Everyone is welcomed to attend. ... M.D. who provides physician-administered skincare, anti-aging, weight loss ...
(Date:7/14/2014)... Many people are unhappy with their ... to reduce a “double chin.” A new product ... to go under the knife. Jawflex is a double ... therefore tightening the skin in that area and reducing ... used for facial exercise, double chin elimination and sagging ...
Breaking Medicine News(10 mins):Health News:Encino Esthetic Dental Group is Now Offering Lumineers and Porcelain Veneers 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 3Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 3Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 3Health News:Jawflex | Double Chin Exercise for Double Chin Reduction 2
... BOSTON, Aug. 6 The Center for Business Intelligence (CBI), a ... which includes Dr. Paul Tang, Vice President and Chief Medical Information ... inaugural Access Federal Stimulus Incentives for Electronic Health Records ... in Alexandria, VA, on September 24-25, 2009. , ...
... unaware there is no cure, survey finds , THURSDAY, Aug. ... mistakenly believe that daily medicine can be taken to prevent ... a widespread lack of knowledge and awareness about food allergy ... adults also found that nearly half of respondents incorrectly believed ...
... , , , , ... Wyse Technology , the global leader in thin computing and ... . Kool Smiles is a rapidly-growing company whose mission is ... Since opening its first office in 2002 in Atlanta, GA, the ...
... , , HOUSTON, ... first patient in a Phase I/II clinical trial of BP-GMAX-CD1, a ... cancer. The disease-specific trial is being conducted under a Bellicum Investigational ... anticipates reporting initial results of the study in 2010. , ...
... MCLEAN, Va., Aug. 6 Sunrise Senior Living, Inc. ... data for the second quarter of 2009. Sunrise will host ... a.m. ET, to discuss the financial results. , , ... of progress in expense controls. In recent weeks we have seen ...
... Greece, August 6 , - Not for Release, Publication or Distribution ... Canada, Australia, South Africa or Japan or, any Other ... Unlawful, - This Announcement is not a Prospectus and is not ... Offer to buy any Securities in the United States or, ...
Cached Medicine News:Health News:CBI Announces the Agenda for Their Upcoming Access Federal Stimulus Incentives for Electronic Health Records Conference 2Health News:Food Allergy Facts Need More Focus 2Health News:Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs) 2Health News:Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs) 3Health News:Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs) 4Health News:Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs) 5Health News:Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 2Health News:Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 3Health News:Sunrise Reports Financial Results for Second-Quarter 2009 2Health News:Sunrise Reports Financial Results for Second-Quarter 2009 3Health News:Sunrise Reports Financial Results for Second-Quarter 2009 4Health News:Sunrise Reports Financial Results for Second-Quarter 2009 5Health News:Sunrise Reports Financial Results for Second-Quarter 2009 6Health News:Sunrise Reports Financial Results for Second-Quarter 2009 7Health News:Sunrise Reports Financial Results for Second-Quarter 2009 8Health News:Sunrise Reports Financial Results for Second-Quarter 2009 9Health News:Sunrise Reports Financial Results for Second-Quarter 2009 10Health News:Sunrise Reports Financial Results for Second-Quarter 2009 11Health News:Sunrise Reports Financial Results for Second-Quarter 2009 12Health News:Sunrise Reports Financial Results for Second-Quarter 2009 13Health News:Sunrise Reports Financial Results for Second-Quarter 2009 14Health News:Sunrise Reports Financial Results for Second-Quarter 2009 15Health News:Sunrise Reports Financial Results for Second-Quarter 2009 16Health News:Sunrise Reports Financial Results for Second-Quarter 2009 17Health News:Sunrise Reports Financial Results for Second-Quarter 2009 18Health News:Sunrise Reports Financial Results for Second-Quarter 2009 19Health News:Sunrise Reports Financial Results for Second-Quarter 2009 20Health News:EANS-News: Alapis Announces its Share Capital Increase to Raise c. EUR 451.1 million 2Health News:EANS-News: Alapis Announces its Share Capital Increase to Raise c. EUR 451.1 million 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: